精神分裂症中的谷氨酸能传递：从基础研究到临床实践。
Glutamatergic transmission in schizophrenia: from basic research to clinical practice.
机构信息
Schizophrenia Research Institute, Nathan Kline Institute for Psychiatric Research, New York, USA.
出版信息
Curr Opin Psychiatry. 2012 Mar;25(2):96-102. doi: 10.1097/YCO.0b013e32835035b2.
Abstract
PURPOSE OF REVIEW
The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.
RECENT FINDINGS
We review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.
SUMMARY
Although evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.
摘要
目的综述
过去 20 年，谷氨酸能假说已从理论发展到新型机制抗精神病药物的 III 期临床试验。
最近发现
我们回顾了关于谷氨酸能理论的最新文献，涵盖了评估和遗传研究，以及动物和人类的药物开发。
总结
尽管支持谷氨酸假说的证据不断增加，但仍需要进一步研究，需要探索与其他关键系统的相互作用。
相似文献
1
Glutamatergic transmission in schizophrenia: from basic research to clinical practice.精神分裂症中的谷氨酸能传递：从基础研究到临床实践。
Curr Opin Psychiatry. 2012 Mar;25(2):96-102. doi: 10.1097/YCO.0b013e32835035b2.
2
[Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].[星形胶质细胞在精神分裂症谷氨酸能神经传递改变中的作用]
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(1):110-117. doi: 10.17116/jnevro201511511110-117.
3
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.N-甲基-D-天冬氨酸受体拮抗剂作用、皮质谷氨酸能功能与精神分裂症：迈向药物研发的范式转变
Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33. doi: 10.1007/s00213-003-1582-z. Epub 2003 Sep 2.
4
Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review.精神分裂症中丘脑的谷氨酸能异常：一项系统综述。
J Neural Transm (Vienna). 2008;115(3):493-511. doi: 10.1007/s00702-007-0859-5. Epub 2008 Feb 26.
5
Decoding schizophrenia.破解精神分裂症
Sci Am. 2004 Jan;290(1):48-55. doi: 10.1038/scientificamerican0104-48.
6
[Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].[代谢型谷氨酸受体在精神分裂症发病机制中的关键作用证据：药物治疗的“突破”]
Riv Psichiatr. 2012 Mar-Apr;47(2):149-69. doi: 10.1708/1069.11719.
7
Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.谷氨酸能神经传递调节与非典型抗精神病药物的作用机制
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1113-23. doi: 10.1016/j.pnpbp.2003.09.007.
8
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.谷氨酸与精神分裂症：苯环己哌啶、N-甲基-D-天冬氨酸受体及多巴胺-谷氨酸相互作用
Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5.
9
Role of glutamate in schizophrenia: integrating excitatory avenues of research.谷氨酸在精神分裂症中的作用：整合兴奋性研究途径。
Expert Rev Neurother. 2008 Sep;8(9):1389-406. doi: 10.1586/14737175.8.9.1389.
10
Biological perspectives: the role of glutamate in schizophrenia and its treatment.生物学视角：谷氨酸在精神分裂症及其治疗中的作用。
Perspect Psychiatr Care. 2012 Jul;48(3):125-8. doi: 10.1111/j.1744-6163.2012.00333.x. Epub 2012 Apr 17.
引用本文的文献
1
A new two-hit animal model for schizophrenia research: Consequences on social behavior.一种用于精神分裂症研究的新型双打击动物模型：对社会行为的影响。
IBRO Neurosci Rep. 2025 May 28;19:38-49. doi: 10.1016/j.ibneur.2025.05.012. eCollection 2025 Dec.
2
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.兴奋性-抑制性平衡作为开发新型抗精神分裂症药物的靶点。
Biochem Pharmacol. 2024 Oct;228:116298. doi: 10.1016/j.bcp.2024.116298. Epub 2024 May 21.
3
The Benzoylpiperidine Fragment as a Privileged Structure in Medicinal Chemistry: A Comprehensive Review.苯甲酰哌啶片段作为药物化学中的优势结构：全面综述。
Molecules. 2024 Apr 23;29(9):1930. doi: 10.3390/molecules29091930.
4
Resting state and activated brain glutamate-glutamine, brain lactate, cognition, and psychopathology among males with schizophrenia: A 3 Tesla proton magnetic resonance spectroscopic (1H-MRS) study.精神分裂症男性患者的静息状态及激活状态下脑内谷氨酸 - 谷氨酰胺、脑乳酸、认知与精神病理学：一项3特斯拉质子磁共振波谱（1H - MRS）研究
Indian J Psychiatry. 2024 Jan;66(1):82-89. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_621_23. Epub 2024 Jan 25.
5
Neuroinflammation and glial cell activation in mental disorders.精神障碍中的神经炎症与胶质细胞激活
Brain Behav Immun Health. 2019 Dec 27;2:100034. doi: 10.1016/j.bbih.2019.100034. eCollection 2020 Feb.
6
Potential Roles for the GluN2D NMDA Receptor Subunit in Schizophrenia.谷氨酸 NMDA 受体 GluN2D 亚单位在精神分裂症中的潜在作用
Int J Mol Sci. 2023 Jul 23;24(14):11835. doi: 10.3390/ijms241411835.
7
Subsequent and simultaneous electrophysiological investigation of the retina and the visual cortex in neurodegenerative and psychiatric diseases: what are the forecasts for the medicine of tomorrow?神经退行性疾病和精神疾病中视网膜与视觉皮层的后续及同步电生理研究：对未来医学有何展望？
Front Psychiatry. 2023 Jun 2;14:1167654. doi: 10.3389/fpsyt.2023.1167654. eCollection 2023.
8
Functional Nutrition as Integrated Intervention for In- and Outpatient with Schizophrenia.功能性营养作为精神分裂症住院和门诊患者的综合干预措施。
Curr Neuropharmacol. 2023;21(12):2409-2423. doi: 10.2174/1570159X21666230322160259.
9
Metabotropic glutamate receptor function and regulation of sleep-wake cycles.代谢型谷氨酸受体功能与睡眠-觉醒周期的调节。
Int Rev Neurobiol. 2023;168:93-175. doi: 10.1016/bs.irn.2022.11.002. Epub 2023 Jan 13.
10
A Reflection Upon the Contribution of Retinal and Cortical Electrophysiology to Time of Information Processing in Psychiatric Disorders.关于视网膜和皮层电生理学对精神疾病信息处理时间贡献的思考
Front Psychiatry. 2022 Apr 5;13:856498. doi: 10.3389/fpsyt.2022.856498. eCollection 2022.
本文引用的文献
1
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.从革命到进化：精神分裂症的谷氨酸假说及其对治疗的启示。
Neuropsychopharmacology. 2012 Jan;37(1):4-15. doi: 10.1038/npp.2011.181. Epub 2011 Sep 28.
2
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.辅助 NMDA 受体调节剂治疗慢性精神分裂症的疗效的荟萃分析。
CNS Drugs. 2011 Oct 1;25(10):859-85. doi: 10.2165/11586650-000000000-00000.
3
Profiles of DARPP-32 in the insular cortex with schizophrenia: a postmortem brain study.精神分裂症患者岛叶皮质中 DARPP-32 的特征：一项尸检脑研究。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1901-7. doi: 10.1016/j.pnpbp.2011.07.010. Epub 2011 Jul 28.
4
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.抑制鼠脑 D-氨基酸氧化酶对 NMDA 受体功能的调制。
Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15. doi: 10.1016/j.neuropharm.2011.06.029. Epub 2011 Jul 7.
5
Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.氯胺酮对大脑功能的影响——视觉Oddball 任务中的 fMRI/EEG 同步研究。
Neuroimage. 2011 Sep 15;58(2):508-25. doi: 10.1016/j.neuroimage.2011.06.045. Epub 2011 Jun 29.
6
D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.地昔环素增强精神分裂症妄想的认知行为治疗。
Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.
7
Effects of low-dose D-serine on recognition and working memory in mice.低剂量 D-丝氨酸对小鼠识别和工作记忆的影响。
Psychopharmacology (Berl). 2011 Dec;218(3):461-70. doi: 10.1007/s00213-011-2330-4. Epub 2011 May 10.
8
NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via Disrupted-In-Schizophrenia 1 (DISC1).NMDA 受体通过精神分裂症相关蛋白 1（DISC1）调节成年海马体中新生成神经元的迁移。
J Neurochem. 2011 Jul;118(1):34-44. doi: 10.1111/j.1471-4159.2011.07282.x. Epub 2011 May 19.
9
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.一项多中心、住院、2 期、双盲、安慰剂对照的 LY2140023 单水合物治疗 DSM-IV 精神分裂症患者的剂量范围研究。
J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5.
10
Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia.精神分裂症患者上颞叶皮层中 DARPP-32 表达的改变。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1139-43. doi: 10.1016/j.pnpbp.2011.03.016. Epub 2011 Mar 29.
Zotero 插件